Reuters.com is your online source for the latest news stories and current events, ensuring our readers up to date with any ...

If approved, AZN's Fasenra will be the second biologic approved in the European Union to treat eosinophilic granulomatosis ...

Shares of AstraZeneca PLC AZN inched down 0.54% to £115.22 Tuesday, on what proved to be an all-around positive trading ...

AstraZeneca topped the analyst consensus for net revenue and matched the analyst consensus for core EPS in Q2. See why I ...

Committee for Medicinal Products for Human Use (CHMP) has recommended approving AstraZeneca’s Fasenra (benralizumab) to treat ...

The uptick in AstraZeneca share price came after the company announced that it has received permission to import for sale and ...

The newly launched “What Science Can Do” campaign, a longstanding tagline for AstraZeneca, centers around the stories of two patients who have benefitted from the company’s therapeutics. Each of their ...

The AstraZeneca PLC ADR AZN slipped 1.58% to $77.14 Monday, on what proved to be an all-around great trading session for the ...

The stock is trading above its 5-day, 10-day, 20-day, 30-day, 50-day, 100-day, 150-day, and 200-day simple moving averages ...

AstraZeneca Pharma India has received approval from the CDSO for the import, sale, and distribution of Durvalumab.

Discover AstraZeneca's groundbreaking patent for dual-target antibody molecules aimed at EGFR and c-Met, paving the way for innovative cancer therapies.

This surge came after the company announced approval to import and distribute Durvalumab (Imfinzi) infusion in two dosages.